Oncolytics Biotech (ONCY) Competitors $0.73 -0.01 (-1.79%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.74 +0.01 (+1.98%) As of 02/21/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ONCY vs. ZYBT, LFVN, VYGR, DSGN, FDMT, LFCR, CCCC, CRDF, SLRN, and LRMRShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Zhengye Biotechnology (ZYBT), LifeVantage (LFVN), Voyager Therapeutics (VYGR), Design Therapeutics (DSGN), 4D Molecular Therapeutics (FDMT), Lifecore Biomedical (LFCR), C4 Therapeutics (CCCC), Cardiff Oncology (CRDF), Acelyrin (SLRN), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Zhengye Biotechnology LifeVantage Voyager Therapeutics Design Therapeutics 4D Molecular Therapeutics Lifecore Biomedical C4 Therapeutics Cardiff Oncology Acelyrin Larimar Therapeutics Oncolytics Biotech (NASDAQ:ONCY) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment. Does the MarketBeat Community believe in ONCY or ZYBT? Oncolytics Biotech received 157 more outperform votes than Zhengye Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformOncolytics BiotechOutperform Votes15768.26% Underperform Votes7331.74% Zhengye BiotechnologyN/AN/A Do institutionals & insiders have more ownership in ONCY or ZYBT? 6.8% of Oncolytics Biotech shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ONCY or ZYBT more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -141.15% -84.73% Zhengye Biotechnology N/A N/A N/A Which has stronger earnings & valuation, ONCY or ZYBT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-$20.56M-$0.27-2.69Zhengye BiotechnologyN/AN/AN/AN/AN/A Does the media refer more to ONCY or ZYBT? In the previous week, Oncolytics Biotech had 8 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 8 mentions for Oncolytics Biotech and 0 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.00 beat Oncolytics Biotech's score of -0.01 indicating that Zhengye Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Oncolytics Biotech Neutral Zhengye Biotechnology Neutral Do analysts prefer ONCY or ZYBT? Oncolytics Biotech currently has a consensus price target of $4.00, indicating a potential upside of 451.27%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Oncolytics Biotech is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryOncolytics Biotech beats Zhengye Biotechnology on 7 of the 10 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.04M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-2.696.1326.4618.82Price / SalesN/A309.83453.2580.30Price / CashN/A67.8344.0437.47Price / Book2.696.747.634.64Net Income-$20.56M$138.11M$3.18B$245.69M7 Day Performance-5.42%-2.43%-1.91%-2.66%1 Month Performance-17.55%-1.91%-0.19%-2.15%1 Year Performance-29.89%-5.03%16.70%12.90% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech1.6613 of 5 stars$0.73-1.8%$4.00+451.3%-28.9%$62.04MN/A-2.6930ZYBTZhengye BiotechnologyN/A$4.99+1.0%N/AN/A$235.38MN/A0.00278Quiet Period ExpirationGap DownLFVNLifeVantage4.1055 of 5 stars$18.56+0.7%$30.50+64.3%+139.1%$232.93M$200.16M33.14260VYGRVoyager Therapeutics4.5275 of 5 stars$4.23-3.4%$15.72+271.5%-44.8%$231.09M$250.01M5.96100Upcoming EarningsNews CoverageDSGNDesign Therapeutics1.784 of 5 stars$4.08+2.8%$7.00+71.6%+81.2%$231.01MN/A-4.8040FDMT4D Molecular Therapeutics3.1263 of 5 stars$4.88+3.4%$32.13+558.3%-82.5%$225.60M$20.72M-1.71120Analyst ForecastLFCRLifecore Biomedical2.6655 of 5 stars$6.09+2.5%$8.00+31.4%-30.1%$225.51M$128.26M-10.88690CCCCC4 Therapeutics2.7279 of 5 stars$3.18-0.6%$11.60+264.8%-58.5%$224.48M$20.76M-1.87150News CoverageCRDFCardiff Oncology2.2144 of 5 stars$4.29+3.4%$10.33+140.9%+182.7%$219.35M$490,000.00-4.5620News CoverageSLRNAcelyrin2.3469 of 5 stars$2.13+3.4%$9.60+350.7%-66.0%$213.70MN/A-0.87135News CoverageGap UpHigh Trading VolumeLRMRLarimar Therapeutics1.5721 of 5 stars$3.34+2.1%$20.13+502.5%-73.5%$213.13MN/A-2.9030 Related Companies and Tools Related Companies Zhengye Biotechnology Competitors LifeVantage Competitors Voyager Therapeutics Competitors Design Therapeutics Competitors 4D Molecular Therapeutics Competitors Lifecore Biomedical Competitors C4 Therapeutics Competitors Cardiff Oncology Competitors Acelyrin Competitors Larimar Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ONCY) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
